Oral News and Research

RSS

Midatech Group, MonoSol Rx file patent to enable commercialization of drug delivery technology

Midatech Group Ltd., a global leader for the design, development, synthesis and manufacture of nanomedicines, and MonoSol Rx, the leader in developing and manufacturing pharmaceutical films based on its proprietary PharmFilm drug delivery technology, today announced the filing of a provisional US patent application for "Nanoparticle Film Delivery Systems." The applications submitted to the United States Patent and Trademark Office (USPTO) relate to therapeutic uses of nanoparticle-based proteins and peptides delivered in pharmaceutical films.

18 Aug 2010

Survey finds variations in general anesthesia, sedation practices among dental care providers

A wide variation has been found in the training for and practice of sedation and general anesthesia within the dental profession in the United States. Safe, effective pain and anxiety control techniques are an essential part of dentistry. A survey designed to be a snapshot of common practices provides insight into this limited area of research.

18 Aug 2010

Chronix Biomedical expands biomarker development capabilities with installation of DNA mass sequencer

Chronix Biomedical today reported that it has significantly expanded and accelerated its biomarker development capabilities with the installation of Germany's first state-of-the-art high-throughput DNA mass sequencer at the University of Göttingen, Chronix's long-time collaborator. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

17 Aug 2010

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.

17 Aug 2010

Elite Pharmaceuticals reports decrease in manufacturing revenue for fiscal first quarter

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and controlled release product formulations, announced results for the fiscal first quarter ended June 30, 2010.

17 Aug 2010

Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN

Xenon Pharmaceuticals Inc. announced today that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of PHN.

17 Aug 2010

Oral contraceptives equally effective for obese women

The first study to compare the effectiveness of the birth control pill in women with marked weight differences has found that the pill works equally well in women with obesity and thinner women. This new finding by physician-scientists at NewYork-Presbyterian Hospital/Columbia University Medical Center refutes a long-held conviction among many doctors that the pill may not reliably prevent pregnancy in women who are overweight or obese.

17 Aug 2010

Ill effects of methamphetamine

On the street it's known as meth, speed, ice, chalk, crank, fire, glass or crystal. Methamphetamine is a highly addictive drug that wreaks havoc on the entire body, including the user's oral health. Approximately 10 million Americans have tried methamphetamine, while more than 1.4 million are habitual users.

17 Aug 2010

Nutrastar second-quarter revenues increase 63.4% to $5.46 million

Nutrastar International Inc., a leading nutraceutical company which produces and distributes Chinese Golden Grass and other specialty food products, today announced financial results for their three and six months ended June 30, 2010.

16 Aug 2010

Emisphere second-quarter net loss increases to $13.7 million

Emisphere Technologies, Inc. today announced financial and operational results for the three and six months ended June 30, 2010.

16 Aug 2010

Liverpool scientists create new drug for malaria

As part of the -1.5 million project, researchers are now testing the drug to determine how the treatment could progress to clinical trials. The drug is made from simple organic molecules and will be cheaper to mass produce compared to existing therapies.

16 Aug 2010

Healthy Lifestyles, Healthy Communities event to provide free medical, dental services in five cities

Henry Schein, Inc., the largest distributor of health care products and services to office-based practitioners, announced today that Healthy Lifestyles, Healthy Communities will provide free medical and dental services to more than 5,000 children and their caregivers in five cities throughout the United States this summer and fall.

16 Aug 2010

August is National Immunization and Cataract Awareness Month

Childhood immunizations keep our children safe from a number of serious diseases. This is a good time of year to make sure your child is up-to-date on all of his/her immunizations. Continue reading to find out which vaccines the Centers for Disease Control and Prevention (CDC) recommend for children 6 and under.

16 Aug 2010

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Adeona Pharmaceuticals, Inc. announced its second quarter 2010 financial results and recent achievements.

16 Aug 2010

Belatacept study data to be presented at 23rd International Congress of The Transplantation Society

Bristol-Myers Squibb Company announced today that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of seven oral clinical presentations related to kidney transplantation at the 23rd International Congress of The Transplantation Society, being held August 15-19, 2010, in Vancouver, British Columbia, Canada. In total, 18 abstracts from company-sponsored studies will be presented during the congress.

16 Aug 2010

Watson to launch ella emergency contraceptive in fourth-quarter 2010

Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.

16 Aug 2010

FDA approves ellaOne for emergency contraception

HRA Pharma announced today that the US Food and Drug Administration (FDA) granted approval for ella(R) (ulipristal acetate) as a prescription-only emergency contraceptive indicated for use within 120 hours (five days) of unprotected intercourse or a known or suspected contraceptive failure. ella is not intended for routine use as a contraceptive.

16 Aug 2010

Study shows early diagnosis of atrial fibrillation reduces risk of stroke

The earlier that patients who suffer from atrial fibrillation obtain the correct treatment, the lower is the risk of serious secondary effects such as stroke. A thesis presented at the University of Gothenburg, Sweden, shows that a well-established measurement score can easily assess the risks for this patient group.

16 Aug 2010

U-M dentistry agrees to use Interleukin's PST test for gum disease clinical study

University of Michigan School of Dentistry has signed an agreement with Interleukin Genetics Inc. to conduct what may be the largest clinical study to date using genetic testing to assess the risk for gum disease.

13 Aug 2010

Interleukin Genetics, University of Michigan to conduct landmark clinical study on periodontal disease

Interleukin Genetics, Inc. announced today that the Company has signed an agreement with the University of Michigan to conduct a landmark clinical study on risk factors predictive of periodontal disease progression to tooth loss using a new version of Interleukin Genetics' PST genetic test.

12 Aug 2010

Oral News and Research

Midatech Group, MonoSol Rx file patent to enable commercialization of drug delivery technology

Survey finds variations in general anesthesia, sedation practices among dental care providers

Chronix Biomedical expands biomarker development capabilities with installation of DNA mass sequencer

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Elite Pharmaceuticals reports decrease in manufacturing revenue for fiscal first quarter

Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN

Oral contraceptives equally effective for obese women

Ill effects of methamphetamine

Nutrastar second-quarter revenues increase 63.4% to $5.46 million

Emisphere second-quarter net loss increases to $13.7 million

Liverpool scientists create new drug for malaria

Healthy Lifestyles, Healthy Communities event to provide free medical, dental services in five cities

August is National Immunization and Cataract Awareness Month

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Belatacept study data to be presented at 23rd International Congress of The Transplantation Society

Watson to launch ella emergency contraceptive in fourth-quarter 2010

FDA approves ellaOne for emergency contraception

Study shows early diagnosis of atrial fibrillation reduces risk of stroke

U-M dentistry agrees to use Interleukin's PST test for gum disease clinical study

Interleukin Genetics, University of Michigan to conduct landmark clinical study on periodontal disease

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News